) The Molecular Biology and Genetics Program is focused on the utilization of genomic information from studies of organisms from yeast to man in the discovery and functional analysis of novel genes responsible for cancer predisposition in """"""""high risk"""""""" populations as well as in sporadic cancers. Cancer development is associated with a series of changes in cellular genes. These changes occur as mutations or variations in gene expression in cancer causing genes and in other genes which respond to them. These genetic alterations provide molecular signatures specific to each tumor type. Cancer susceptibility genes frequently cause so-called """"""""genomic instability"""""""" in which cells develop DNA damage in critical cancer-causing genes such as oncogenes and tumor suppressor genes. Both germline or somatic mutations affect proteins involved in signal transduction such as growth factor receptor pathways or transcription factors leading to changes in gene expression. Studies in human populations at extreme risk to cancer can be applied to the general population in which the genetics of cancer risk is more subtle. The current efforts of this program are on mechanisms of genomic instability, chromatin structure, cell cycle checkpoint control, transcriptional regulation of signal transduction, and post-translational control mechanisms. We utilize cell lines and whole animals to model the genetic mechanisms leading to precancerous cells, the molecular signatures of precancerous lesions, and the critical genetic events in the progression of these cells to neoplasia. Because of the extensive body of genetic information on DNA repair genes and growth control mechanisms in model organisms, we are applying the genetics of yeast and mouse model systems to understand human gene structure and function. We are analyzing the human homologues of well characterized yeast DNA repair and checkpoint genes for their role in genetic and sporadic human cancers. These genetic mechanisms will provide useful molecular targets for cancer detection, chemoprevention and chemotherapy. This body of knowledge also provides a novel approach to cancer risk determination in special populations available in the patient base associated with the Karmanos Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-22
Application #
6457239
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1988-04-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597
Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697
Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4
Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133

Showing the most recent 10 out of 826 publications